Understanding drug resistance for monotherapy treatment of HIV infection (Q1364700): Difference between revisions

From MaRDI portal
RedirectionBot (talk | contribs)
Changed an Item
Created claim: Wikidata QID (P12): Q44348252, #quickstatements; #temporary_batch_1726327587925
 
(2 intermediate revisions by 2 users not shown)
Property / MaRDI profile type
 
Property / MaRDI profile type: MaRDI publication profile / rank
 
Normal rank
Property / cites work
 
Property / cites work: A model for treatment strategy in the chemotherapy of AIDS / rank
 
Normal rank
Property / cites work
 
Property / cites work: A Mathematical Model of Combined Drug Therapy of HIV Infection / rank
 
Normal rank
Property / cites work
 
Property / cites work: Dynamics of HIV infection of CD4\(^ +\) T cells / rank
 
Normal rank
Property / Wikidata QID
 
Property / Wikidata QID: Q44348252 / rank
 
Normal rank

Latest revision as of 16:29, 14 September 2024

scientific article
Language Label Description Also known as
English
Understanding drug resistance for monotherapy treatment of HIV infection
scientific article

    Statements

    Understanding drug resistance for monotherapy treatment of HIV infection (English)
    0 references
    0 references
    0 references
    19 October 1999
    0 references
    A deterministic mathematical model is developed to investigate monotherapy treatment strategies of HIV patients in the presence of drug-resistant mutant HIV strains. The model is a nonlinear system of differential equations for the following five variables: the infected \(\text{CD}4^+\) \(T\) cells \(T(t)\), the wild-type virus and the mutant virus infected \(T\) cells \(T^s(t)\) and \(T^r(t)\), and the wild-type and the mutant viral load \(V_s(t)\) and \(V_r(t)\), respectively. Model features allow infection of \(T\) cells by both sensitive and resistant strains, release of newly produced virion, growth, mutation, clearance of virion, and \(T\) cell proliferation. Monotherapy is modeled for a variable time window by reduction of viral infectivity. This is implemented by multiplying the infection rate of \(T\) cells by free virus \(V_s\) and by multiplying with a treatment effectiveness parameter \(P_1\). A similar parameter \(P_2\) is applied to the external lymphoid system. A total of 27 model parameters -- 9 time dependent - are specified from clinical data. A numerical simulation study is performed to model the above described five variables for different treatment schedules on an individual basis. The results are compared qualitatively with clinical \(\text{CD4}^+T\) cell courses from 6 key AIDS studies performed between 1990 and 1995. Treatment benefit is based on increase or retention of \(\text{CD4}^+T\) cell counts and on low viral titer. Best monotherapy treatment effect is suggested by this model when the treatment starts in a middle region of \(250/\text{mm}^3\) to \(400/\text{mm}^3\) of \(\text{CD}4^+\) cell count and when a careful balance beteen mutant and wild-type HIV strains is achieved.
    0 references
    0 references
    AIDS model drug resistance
    0 references
    HIV infection treatment
    0 references
    deterministic model
    0 references

    Identifiers